4-(methoxycarbonyl)-9H-fluoren-9-one oxime (Z) | 5043-64-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 4-(methoxycarbonyl)-9H-fluoren-9-one oxime (Z)
• 英文别名: methyl 9-(hydroxyimino)-9H-fluorene-4-carboxylate；methyl (9Z)-9-hydroxyiminofluorene-4-carboxylate
• CAS: 5043-64-1
• 化学式: C₁₅H₁₁NO₃
• 分子量: 253.257
• InChiKey: NGVLXRBIJYFIFM-PEZBUJJGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2928000090

文献信息

• Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof
  申请人：MAILLIET Patrick

  公开号：US20080153837A1

  公开（公告）日：2008-06-26

  This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

  这项发明涉及4-(苯并咪唑-2-基)芴和4-(氮杂苯并咪唑-2-基)芴的衍生物，涉及包含这些衍生物的药物组合物，以及涉及治疗与Hsp90蛋白活性相关的疾病的方法，包括给予这些衍生物。
• THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES
  申请人：RICCIARDI Robert P.

  公开号：US20100035887A1

  公开（公告）日：2010-02-11

  This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.

  本发明提供了一种通过将痘病毒与具有公式I、公式XXI、公式XXXII或公式XLI的化合物接触来抑制痘病毒复制的方法，进而减少、抑制或消除痘病毒DNA聚合酶活性和/或其与其过程性因子的相互作用。公式I、公式XXI、公式XXXII或公式XLI可用于治疗患有痘病毒感染的人类和动物。还提供了用于治疗痘病毒感染受试者的药物组合物。
• Small molecule toll-like receptor (TLR) antagonists
  申请人：Lipford B. Grayson

  公开号：US20070232622A1

  公开（公告）日：2007-10-04

  The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.

  本发明提供了用于调节通过Toll样受体信号传导的方法和组合物。该方法涉及使用一个包含至少两个环的核心结构的小分子接触TLR表达的细胞。其中某些化合物是4-主氨基喹啉。许多化合物和方法特别适用于抑制至少一个TLR9、TLR8、TLR7和TLR3的免疫刺激。该方法可能在治疗自身免疫、炎症、过敏、哮喘、移植排斥、移植物抗宿主病、感染、败血症、癌症和免疫缺陷方面有用。
• NOUVEAUX DERIVES DU FLUORENE, COMPOSITIONS LES CONTENANT ET UTILISATION
  申请人：Aventis Pharma S.A.

  公开号：EP1888579A2

  公开（公告）日：2008-02-20
• US7410975B2
  申请人：——

  公开号：US7410975B2

  公开（公告）日：2008-08-12